Home Compare AZN.L vs LLY
Stock Comparison · Industry comparison · Drug Manufacturers - General

AstraZeneca vs Eli Lilly and Company: Which Stock Looks Stronger in 2026?

Eli Lilly and Company holds the cleaner structural position, with profitability as the main driver and stability adding further support. AstraZeneca still has the edge on stability, which keeps the comparison from looking entirely one-sided. On the market side, Eli Lilly and Company is in better shape — its trend is intact while AstraZeneca's trend has broken down. That puts structure and market broadly in agreement — Eli Lilly and Company's lead looks more confirmed than conflicted.

The comparison is based on similar long-term financial trajectories, not sector labels. Peer scores are normalised within each company's primary universe (AZN.L: STOXX 600, LLY: S&P 500).

Updated 2026-08-16

Most of the separation is still concentrated in profitability. Eli Lilly and Company leads by 13 points on the overall comparison score.

INDUSTRY COMPARISON

Both operate in: Drug Manufacturers - General

This comparison is based on industry proximity, not on functional trajectory similarity. AZN.L and LLY share the same industry classification.

For a similarity-based comparison, see how AstraZeneca and Eli Lilly and Company each position within their functional peer groups in AssetNext.

Peer-Relative Score
AZN.L
AstraZeneca PLC
53
Peer-Score
Signal qualityHigh
Peer basis: STOXX 600
vs
LLY
Eli Lilly and Company
66
Peer-Score
Signal qualityHigh
Peer basis: S&P 500

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The largest gaps do not all point in the same direction.

Dimension spread: AZN.L vs LLY Profitability 41 100 Stability 58 34 Valuation 54 46 Growth 65 75 AZN.L LLY
Gap Ranking
#1 Profitability +59
#2 Stability +24
#3 Growth +10
#4 Valuation +8
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for AZN.L and LLY Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer AZN.LLLY Relative valuation Structural strength

Eli Lilly and Company occupies the cheaper side of the setup map, although AstraZeneca PLC still holds the stronger structural profile.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Profitability
Both profiles are strong on profitability, but Eli Lilly and Company leads clearly.
Stability
AstraZeneca PLC sits in the stronger part of the group on stability, while Eli Lilly and Company is closer to mid-pack.
Profitability — Dominant Gap
AZN.L
41
LLY
100
Gap+59in favour of LLY

The profitability lead is mainly driven by a 31-point operating margin advantage.

What keeps the gap from being one-sided

AstraZeneca PLC still carries lower volatility exposure — that difference is real enough to prevent the comparison from becoming one-sided.

What this means for the comparison

The profitability lead is clear, but pricing and stability still pull in the other direction — the result holds, but not without friction.

Explore full peer positioning in AssetNext

Break down the AZN.L vs LLY comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Other comparisons with conflicting dimension signals

Explore how AZN.L and LLY each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.